BHOC Therapeutics
Research, evidence and material developments relevant to BHOC / HBOC, donor-blood logistics, emergency transfusion and tissue oxygenation through Precision Oxygen Therapeutics.
The RESUS research agreement, Senator Edward M. Kennedy and Carl W. Rausch: revisiting the people and institutions behind Biopure's oxygen-therapeutics development.
The 2001 New York Times coverage of Hemopure, Carl W. Rausch and David N. Judelson highlights the scientific, industrial and leadership work behind Biopure.
Carl W. Rausch and Archil Jaliashvili review component variability, oxygen function and measurement uncertainty, with thanks to the colleagues who helped prepare the manuscript.
A DARPA award of up to $120 million highlights severe hemorrhage care. BHOC connects bleeding control with tissue oxygenation and small-volume oxygen support.
Two independent US consultations raise a broader emergency-care question: how can perfusion, oxygen diffusion and tissue oxygenation be assessed before donor blood arrives, including in myocardial ischemia?
SANBS needs 3,500 donated units daily across eight South African provinces. A comparison of reserve targets and preparedness for longer supply disruption.
The published model estimates approximately 1.1 million blood units collected annually for about 21,000 blood-equipped EMS vehicles.
More than 19,000 people are living with sickle cell disorder in England, but closely matched red-cell supply is not keeping pace with transfusion demand.
WHO's 2026–2030 action plan connects donation with financing, regulation, quality systems, infrastructure and timely patient access.
Hemostasis Today’s Voices section features Archil Jaliashvili’s perspective on BHOC as a potential complementary oxygen-delivery bridge in postpartum hemorrhage research.
When life hangs in the balance, oxygen must reach tissues and cells. Mr. Chris Treble reflects on this biological need and the purpose behind BHOC development of Precision Oxygen Therapeutics.
What is standardized, what is actually transfused and when is the response measured? A source-linked review of RBC dose variability, component standards and the interpretation of transfusion outcomes.
Listening to the people this work is for, sharing their questions and answering them openly. The new section begins with Jeff Parke and Cold Ischemia Foundation.
Revisiting Levien’s clinical report from South Africa and a shift in emphasis from red-cell replacement toward tissue oxygenation.
WHO's renewed preparedness commitments raise a practical question: could Precision Oxygen Therapeutics based on Biological Hemoglobin Oxygen Carriers contribute to oxygen-delivery resilience and Strategic Sovereign Reserves when donor-dependent blood supply is disrupted?
A new BHOC policy-evidence analysis connects WHO priorities on stockpiles, emergency supply chains and local manufacturing with the research question of oxygen-delivery resilience.
The RESUS amendment described a conditional defense contingency provision for HBOC-201. It specified 1,500 units and Biopure’s estimated total cost ceiling of $650 per unit if NMRC made a written request.
Carl W. Rausch and Archil Jaliashvili propose a function-first framework that shifts the question from replacing blood toward controlled microvascular and tissue-level oxygen delivery.
March concerned a patient’s own stored blood. September extended individual decision-making to red cells, white cells, plasma and platelets from another person’s blood, while the position on whole blood remained unchanged.
The published clinical record documents multiple survivors after HBOC-201 was used in life-threatening anemia when conventional red-cell transfusion was unavailable or could not be used, including Jehovah’s Witness patients.
At the 20th International Symposium on Blood Substitutes, Bing-Lou Wong, PhD, presented “Beyond the ‘Blood Substitute’ Paradigm: Evolution of HBOCs as a Precision Oxygen Therapeutic Infrastructure.”
On September 29, 1999, Carl W. Rausch placed blood shortages, readiness costs and donor-independent oxygen delivery before the Joint Economic Committee of the U.S. Congress. More than a quarter-century later, the technology has changed. The physiological question has not.
EMS.gov now gives prehospital blood transfusion dedicated visibility and features a special 2026 series on how EMS agencies can build and operate prehospital blood programs.
Three recent evidence signals point to the same system problem: emergency care must evaluate oxygen delivery by function, access, timing and readiness, not by the transfusion product alone.
Nine-year-old Qasim Rizwan had a rare red-cell profile that included the r’r’ phenotype. NHS Blood and Transplant sent all six matching frozen units held in its national bank, followed by another unit from Colindale, and called a rare donor specifically for him.
Rwanda pioneered national medical drone delivery, Ghana scaled the model, and Shenzhen is integrating drone blood transport into a large, technology-enabled hospital network. The bigger story is not the drone itself. It is where real medical innovation gets implemented first, and why.
The proposed sixth edition addresses technology infrastructure, AI governance, informed consent and review of adverse-event trends.
A study of 25,473 trauma patients found that simple prehospital criteria identified a group in which 52% received blood within four hours; the best-performing criterion reached a PPV of 56%.
Real-world studies examine oxygenated machine perfusion, donor liver assessment and organ viability across large transplant cohorts.
Official blood-service reports show how seasonal illness, weather, donor availability and inventory dynamics can place pressure on mature national blood systems.